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Abstract: Global healthcare expenditure is escalating at an unsustainable rate. Money spent on 
medicines and managing medication-related problems continues to grow. The high prevalence of 
medication errors and inappropriate prescribing is a major issue within healthcare systems, and 
can often contribute to adverse drug events, many of which are preventable. As a result, there is 
a huge opportunity for pharmacists to have a significant impact on reducing healthcare costs, as 
they have the expertise to detect, resolve, and prevent medication errors and medication-related 
problems. The development of clinical pharmacy practice in recent decades has resulted in an 
increased number of pharmacists working in clinically advanced roles worldwide. Pharmacist-
provided services and clinical interventions have been shown to reduce the risk of potential 
adverse drug events and improve patient outcomes, and the majority of published studies show 
that these pharmacist activities are cost-effective or have a good cost:benefit ratio. This review 
demonstrates that pharmacists can contribute to substantial healthcare savings across a variety 
of settings. However, there is a paucity of evidence in the literature highlighting the specific 
aspects of pharmacists’ work  which are the most effective and cost-effective. Future high-quality 
economic evaluations with robust methodologies and study design are required to investigate 
what pharmacist services have significant clinical benefits to patients and substantiate the great-
est cost savings for healthcare budgets.
Keywords: pharmacoeconomics, pharmaceutical care, clinical pharmacy, cost-effectiveness, 
economic evaluation
Introduction
The role of the pharmacist has evolved substantially in recent decades. The traditional 
activities of the profession primarily focused on the dispensing and supply of medi-
cations, while interaction with other healthcare professionals was somewhat limited. 
Nowadays, pharmacists also ensure the rational and cost-effective use of medicines, 
promote healthy living, and improve clinical outcomes by actively engaging in direct 
patient care and collaborating with many healthcare disciplines. With this expanding 
scope of practice, pharmacists are being recognized as key components in providing 
individualized patient care as part of interprofessional healthcare teams.
Escalating healthcare costs
Healthcare costs are rising worldwide, due to the combination of an aging population, 
technological advances, the prevalence of medication errors, and increased spending 
on medicines year on year.1 As the global population ages, healthcare organizations are 
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challenged with the increasing burden of chronic diseases and 
polypharmacy among older adults.2 The increased number 
of medicines being consumed by the elderly, as well as the 
rising cost of newer pharmacotherapies, has intensified the 
pressure on healthcare organizations to identify and imple-
ment cost-control measures. Pharmacists have a major role 
in lowering costs by critically reviewing the pharmacotherapy 
of multimorbid elderly patients. The reduction of inappro-
priately prescribed medicines not only produces savings in 
the cost of each individual medicine but also reduces the 
risk of adverse drug events (ADEs) that often contribute to 
prolonged and expensive hospital admissions.
Under constrained financial conditions, healthcare ser-
vices need to demonstrate that they remain cost-effective, 
given the investment in their provision.3 Numerous publi-
cations describe the diversifying role of pharmacists in a 
variety of practice settings,4,5 and these are not just limited 
to developed countries.6 Previous review articles have shown 
positive economic outcomes associated with pharmacist 
interventions and clinical pharmacy services. However, 
despite these developments, this has not diminished the need 
to prove continually the economic benefit of such services, 
as some of the papers included in these review articles did 
not include full economic evaluations.5,7–10
Pharmacoeconomics, cost savings, and 
cost avoidance
The continuing high cost of medicines emphasizes the 
increasing importance of pharmacoeconomic evaluation stud-
ies.11 These studies allow us to identify, measure, and compare 
the cost of different pharmacotherapies or services and what 
significance they will have on healthcare budgets and patient 
health. In this field, pharmacists can have a major influence 
on healthcare decision makers with regard to better alloca-
tion of resources and expenditure, so as to optimize popula-
tion health from the use of medicines.12 With their unique 
knowledge of medicines, pharmacists are central figures in 
decreasing healthcare expenditure through cost savings on 
medicines and cost avoidance. Cost savings allude to reduc-
tions in current spending due to changes in the expense on 
a patient’s treatment, eg, switching from intravenous to oral 
therapy where appropriate. In contrast, cost avoidance refers 
to an intervention that reduces potential future spending that 
may have occurred without the intervention. An example of 
this would be a pharmacist suggesting the discontinuation of a 
potentially inappropriate medicine in an elderly patient  which 
could result in a future ADE, hence reducing the potential 
cost of a general practitioner (GP) referral or hospital admis-
sion, as well as eliminating the actual cost of the medicine.3 
Over an extended period of time, limiting costs through cost 
avoidance measures can result in significant cost savings.
Medication errors, inappropriate 
prescribing, and ADEs
Medication errors and inappropriate prescribing are recog-
nized as major problems, both clinically and economically, 
for the healthcare system. They can contribute to adverse drug 
reactions (ADRs) and ADEs, especially in elderly patients, 
and can have a major impact on patient morbidity and mortal-
ity.13 ADEs can result in increased healthcare utilization, as 
well as extend hospital admissions, hence incurring further 
medical costs.14 One large study demonstrated that ADRs 
were responsible for 6.5% of hospital admissions,15 while a 
recent meta-analysis showed that ADEs may occur in 16.88% 
of patients during hospitalization.16 Patients affected by an 
ADE have their hospital admission prolonged by an average 
of 2 days, at an additional expense of ~US$2,000–$2,500.17 
Medication errors are very costly to healthcare systems, but 
a large portion of these are preventable.18–20 Pharmacists 
have demonstrated a positive effect in preventing medication 
errors and limiting inappropriate prescribing, thus reducing 
healthcare costs by preventing hospital admission or reducing 
hospital length of stay (LOS).21
Aim
The aim of this paper was to provide a comprehensive nar-
rative overview of the role of pharmacists in reducing costs 
in a variety of different healthcare settings.
Materials and methods
A comprehensive electronic literature search was conducted 
using the following databases from inception up to and includ-
ing November 2016: PubMed, Medline (Ovid), CINAHL, Sci-
ence Direct, and Google Scholar. Key search terms included 
but were not limited to: “pharmacist” AND “cost” AND 
“economic evaluation” AND “hospital” AND “community 
pharmacy”, as well as various synonyms or combinations of 
these terms. Other search methods included citation search-
ing and scanning reference lists of highly cited key papers.
Community pharmacists
The long-established image of community pharmacists has 
been based on a transactional model, primarily focused on 
the preparation, dispensing, and supply of medicines. How-
ever, this profession has transformed considerably in recent 
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Pharmacist role in cost reduction
 providing services and playing a greater role in health pro-
motion and disease prevention. Community pharmacists are 
one of the most accessible healthcare providers and hence 
are in a unique position to provide a patient-focused primary 
healthcare service to their community.
Most primary care physicians do not have enough time 
to provide all of the preventive and chronic disease services 
that patients require, and this is where other members of the 
multidisciplinary team can make a valuable contribution in 
picking up any shortfalls.22 Pharmacists can play a vital role 
in filling many of these gaps, as they have more time and the 
appropriate expertise to provide high-quality patient-centered 
health care.10
Chronic disease management
Chronic diseases are the leading cause of death and disability 
worldwide, and their management accounts for more than two-
thirds of global healthcare expenditure.23,24 Pharmacists have the 
potential to play a greater role in the management of chronic 
illnesses and make considerable savings in healthcare costs. 
As frontline healthcare professionals, community pharmacists 
are in contact with this patient cohort regularly, are specially 
trained to reduce disease severity, monitor medication therapy 
to achieve desired clinical effects, reduce adverse health events, 
and can make recommendations to patients or prescribers 
regarding pharmacotherapy where appropriate. Studies have 
shown that pharmacists in primary care have the skills to man-
age patients with long-term conditions, and this can result in 
both clinical and cost benefits for a variety of chronic illnesses, 
such as cardiovascular disease, chronic obstructive pulmonary 
disease, and diabetes.25–27 The expanded role of pharmacists 
managing chronic diseases is commensurate with the extensive 
training and knowledge associated with the profession.28
Community pharmacists are ideally placed to undertake 
health screenings for disease prevention and progression, 
and to aid in the diagnosis of new diseases (eg, type 2 diabe-
tes).  Pharmacy-based health checks have been shown to be 
cost-effective when actively screening at-risk patients.29 The 
delivery of point-of-care testing in community pharmacies 
may be used not only for screening purposes but also in the 
management of chronic diseases. Although these services 
may incur initial costs, such as training and purchase of 
equipment, their provision in this setting can reduce patient 
attendance at time-constrained GP offices, as well as allow 
patients to conveniently check clinical parameters such as 
cholesterol, blood glucose, and HbA
1c
, and receive their results 
in a timely manner. Community pharmacists can utilize this 
information to monitor the patients’ control of their chronic 
disease and improve clinical outcomes.30
In the management of hypertension, pharmacists have 
been shown to improve patient outcomes and represent a 
cost-effective alternative in comparison to those managed by 
physicians.31 Community pharmacy-managed anticoagula-
tion services have been shown to improve chronic anticoagu-
lation control with decreased bleeding and thromboembolic 
events.32 When compared with usual medical care, one 
study found that pharmacist-run services made savings of 
$647,024 by preventing hospital admissions and emergency 
department (ED) visits.33 The clinical and economic benefits 
of community pharmacist involvement in chronic disease 
management have been well defined. It is envisioned that 
community pharmacists can take on greater roles in chronic 
disease management and help generate significant healthcare 
cost savings in the future.
Adherence
Medication adherence may be defined as “the extent to which 
patients take medications as prescribed by their healthcare 
providers”.34 Even though good medication adherence cor-
relates with positive health outcomes,35 it is estimated that 
between 20% and 50% of patients in developed countries 
may be nonadherent with their medications.36,37 Nonadher-
ence is associated with potential disease progression, phar-
macotherapeutic failure, and hospitalization.38 A study from 
the US found that 33%–69% of medication-related hospital 
admissions may be due to poor medication adherence.34
Medication nonadherence is an economic burden world-
wide, and it is estimated that the annual cost of nonadherence 
is $100 billion in the US alone.39 Although improvements 
in adherence lead to increased spending on medicines, this 
results in an overall reduction in medical costs.40 Therefore, 
an intensive effort is required to improve patients’ adherence 
to their pharmacotherapy. Community pharmacists can have 
a major impact on patient adherence, as they are uniquely 
positioned to identify patients who may not be taking their 
medicines as prescribed, the reasons for this, and can inter-
vene at the point of medication supply by providing educa-
tion and counseling where appropriate. Studies have shown 
that pharmacists can improve medication adherence rates, 
resulting in improved patient outcomes.41,42 However, more 
research must be done to evaluate the true economic benefits 
of such interventions.
Medicines use review
It is important to highlight that patients’ use of medicines 
should be reviewed for appropriateness before adherence is 
encouraged. This is particularly the case with elderly patients, 
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have adverse consequences. A medicines use review (MUR) 
involves a private discussion between a pharmacist and a 
patient, whereby the goal is to improve the patient’s knowl-
edge, adherence, and use of medicines.43 MURs also provide 
an opportunity for a pharmacist to review a patient’s phar-
macotherapy, including both prescribed and over-the-counter 
(OTC) medicines. Pharmacists can identify which medicines 
a patient may not be taking, as well as potentially inappro-
priate medicines, helping to reduce wastage and optimize 
care. It was estimated in 2009 that the gross annual cost of 
the National Health Service (NHS) primary care and com-
munity care prescription medicine wastage was £300 million 
per year in England, including £90 million worth of unused 
prescription medicines that are retained in individuals’ homes 
and £110 million returned to community pharmacies.44 With 
an aging multimorbid population worldwide, polypharmacy 
will continue to be a serious issue, and hence MURs by 
community pharmacists will be significant in order to curb 
healthcare costs. Even though robust research evidence is 
lacking with regard to the clinical and cost-effectiveness of 
MURs, a recent article found that their value is now largely 
accepted, and that the benefit of these MURs outweighs any 
costs that they may incur.45
Selection of OTC items
The number of medicines available without a prescription 
is growing rapidly; there are currently over 300,000 OTC 
medicinal products available in the US market alone.46 
Pharmacists play an important role in safeguarding their 
patients, especially the elderly, from potentially inappropri-
ate use of OTC medicines. Pharmacists often provide advice 
or nonpharmacological approaches as first-line solutions, 
hence saving on the cost of purchasing an OTC item unnec-
essarily.47 If an OTC product is required, pharmacists help 
their patients choose a safe and appropriate option tailored 
to their individual needs. Pharmacists recommend using 
generic medicines rather than high-cost branded alternatives, 
reducing the cost to the patient and healthcare system. Self-
medication with OTC products has been shown to contribute 
to ADRs and hospital admissions.48 With the advice and 
recommendations of a community pharmacist, patients can 
avoid spending money on ineffective or potentially harmful 
OTC medications; this helps limit further healthcare utiliza-
tion by patients, such as GP or ED visits.
Management of minor ailments
According to a recent report in the UK, 5% and 13% of 
presentations to EDs and GPs, respectively, represent minor 
ailments that could be managed in community pharmacies.49 
In this way, community pharmacists can play an important 
role in reducing the clinical and economic burden of  minor 
ailment consultations on other higher cost areas of the health 
service. Pharmacists are specially trained in managing these 
self-limiting conditions and deal with them daily as part of 
their normal practice, such as colds and flu, hay fever, and 
various aches and pains.50 Pharmacists can provide first aid to 
patients free of charge in the management of minor injuries 
to help avoid or reduce potentially costly trips to the ED. 
Community pharmacists are available at convenient hours and 
usually require no appointment, helping to keep minor ail-
ments out of the GP setting but also ensuring that patients with 
potentially serious illnesses are filtered through to their GP.51
State-funded minor ailment schemes are available across 
the UK and Canada,52 whereby pharmacists provide consulta-
tions to patients for a wide variety of minor ailments. Patients 
who are exempt from prescription charges receive the medi-
cines free of charge, whereas patients who routinely pay for 
their medicines must pay the pharmacy a standard prescrip-
tion charge. The government reimburses the pharmacy for 
the cost of the medicine and provides remuneration for the 
pharmacist’s time. These repayments should allow for further 
development of pharmacy services. Other countries, such as 
New Zealand, are currently evaluating the feasibility of intro-
ducing similar minor ailment schemes, while a pilot study is 
being undertaken in Ireland.53,54 A UK report suggested that 
GPs treating minor ailments is costing the NHS £2 billion 
per year.55 Community pharmacy minor ailment schemes can 
save physician time spent with minor illnesses and enables 
them to focus on patients with more complex medical issues. 
This may contribute to shorter waiting times, unclogged GP 
surgeries, and enhanced patient access to services.56
The cost benefits of minor ailment schemes are clear. 
Patients consulting more costly branches of the healthcare 
system for minor ailments that could have been dealt with 
in a community pharmacy is a waste of resources, patients’ 
time, and GPs’ time.50 Studies have shown that community 
pharmacists’ management of minor ailments, as well as the 
patients’ health-related outcomes, is equivalent to those seen 
in higher cost settings.49 Additional economic evaluations 
will be required to highlight the continuing cost benefits that 
these schemes can achieve.
Other services available in community 
pharmacies
The delivery of additional services through community phar-
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Pharmacist role in cost reduction
and government-funded healthcare systems. Expanding the 
number of medicines and services that community pharma-
cists can provide can reduce patients’ requirements to seek 
more expensive areas of the healthcare sector. For example, 
timely access to emergency hormonal contraception without 
prescription has been a welcome addition to community 
pharmacies worldwide, avoiding any extra expense or time 
delay in consulting with a physician.57
Pharmacy-provided vaccination services have expanded 
the scope of practice for pharmacists, and they resemble 
a lower cost substitute when compared to those that are 
physician-administered.58 It has been shown that immu-
nization rates against influenza are significantly higher 
for individuals aged >65 years in areas where pharma-
cists provide vaccinations,59 most likely due to improved 
accessibility and convenient locations for patients to be 
vaccinated in pharmacies.60 Increased vaccination rates 
have been shown to reduce deaths and hospitalizations 
in elderly patients, and thus increased vaccination rates 
should translate into more cost savings due to reductions 
in direct medical care.61
Hospital pharmacists
Hospital pharmacists have had a major influence on the 
advancement of pharmacy practice in recent decades.62 In 
many countries, hospital pharmacists have expanded their 
roles beyond the dispensary, and now routinely provide 
clinical pharmacy services at ward level, which includes 
reviewing patients’ medications and advising other healthcare 
professionals with regard to pharmacotherapy.63 However, 
in several regions worldwide, the evolution of hospital-
pharmacy practice is not happening quickly enough. In these 
areas, particularly in some parts of Africa and Asia, hospital 
pharmacists have been predominantly limited to dispensary-
based roles, meaning that their expertise in medicine manage-
ment is being underutilized.62,64
Hospital pharmacists represent a key component of the 
multidisciplinary team involved directly in patient-centered 
care. When delivered as a core clinical service, pharmacist-
managed medication therapy has been associated with 
reduced medication errors, ADRs, mortality, and LOS.65 In 
many developed countries, hospital pharmacists are working 
at advanced levels clinically in a wide array of specialized 
roles,63 with an increased number of independent and/or 
supplementary pharmacist prescribers.66 Specialization 
allows pharmacists to deliver enhanced care to patients or 
to a selected group of patients, and hence may prove to be 
beneficial in reducing expenditure for healthcare providers.67 
In order to justify the provision of additional pharmacy 
services, it is no longer adequate to substantiate the clini-
cal benefits of the service alone. Cost-effectiveness data 
is a necessity.68 Several review articles have demonstrated 
the overall cost-effectiveness of hospital pharmacists’ 
activities in a wide variety of clinical specialties, such as 
ED and intensive care unit (ICU) pharmacists, pharmacists 
managing therapeutic drug monitoring of antibiotics and 
antiepileptics, and those who specialize in the optimiza-
tion of antimicrobial therapy.4,8,10,68–70 However, some of the 
economic evaluations only contained partial cost analyses; 
therefore, this may limit the strength of the conclusions 
provided.8,10
Hospital pharmacists’ clinical activities often include 
medicines reconciliation at transition points of care, medi-
cation management reviews for inpatients, provision of 
medicines information to other healthcare professionals, 
selection of drug therapy, monitoring patients for an appro-
priate therapeutic response to medicines, identifying and 
reporting ADRs, patient counseling, as well as other duties 
to ensure the safe and effective use of medicines in this set-
ting.71 Pharmacist interventions are a key component to a 
hospital pharmacist’s role in preventing medication-related 
problems (MRPs) and have been defined as “any action by a 
clinical pharmacist that directly results in a change in patient 
management or therapy”.72 Evidence from the literature is 
quite mixed with regard to the cost-effectiveness of phar-
macists’ interventions and related measures, such as health 
outcomes and quality of life.73 However, many studies have 
proven that pharmacist interventions have a positive impact 
on hospital budgets, but it is difficult to elucidate which 
interventions were the most cost-effective.74,75 Cost-saving 
interventions often include discontinuing unnecessary 
medicines, switching to less expensive agents, or altering 
the route of administration.76 However, previous research has 
suggested that cost avoidance measures, such as preventing 
ADEs and further healthcare utilization, have the greatest 
cost:benefit ratio.68 Cost avoidance calculations in this set-
ting are usually based on ADE probability in the absence of 
pharmacist intervention.9 ADEs can cause hospitalization 
or prolong LOS and may even result in serious harm or 
death. Reducing LOS is the key to cost savings. Therefore, 
by preventing ADEs and shortening LOS over a period 
of time, pharmacists can make substantial cost savings in 
healthcare budgets.3 In this way, hospital pharmacists act 
as risk managers by eliminating additional costs due to 
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Medicines reconciliation and transitions 
of care
Although it is one of the more challenging aspects of 
inpatient care, medicines reconciliation has been proven to 
reduce medication errors and subsequent harm to patients 
at transition points of care.21,78 An accurate medication list 
at hospital admission in particular is vital when evaluat-
ing patients’ current pharmacotherapy and in determining 
further treatment options.79 Studies have established that 
best possible medication histories attained by pharmacists 
are more precise and more comprehensive than those 
obtained by other healthcare practitioners.80 Furthermore, 
pharmacist-led reconciliation has been shown to have the 
highest expected cost benefits when compared with other 
reconciliation processes.81
However, a recent systematic review revealed that under-
taking medicines reconciliation alone at discharge is insuf-
ficient in reducing postdischarge clinical outcomes, and that 
the approach should be multifaceted, incorporating a clinical 
medication review during admission and patient counseling. 
Consequently, hospital pharmacists are being given the oppor-
tunity to take up more proactive roles in the management of 
patients’ care transitions, where there is an increased risk of 
medication error.82 A cost-effectiveness evaluation indicated 
that discharge counseling by pharmacists was cost saving in 
48% of scenarios, but all scenarios were cost-effective at a low 
willingness-to-pay value. High-risk elderly patients appeared 
to benefit most from this service.83 It has been shown that 
pharmacists’ involvement at admission and discharge has 
resulted in reduced medication errors and ADEs, as well as 
a substantial decrease in the rate of all-cause ED visits and 
hospital readmissions.21,78 Although these outcomes should 
produce significant cost savings for healthcare providers, fur-
ther studies must be conducted to quantify the exact economic 
benefits of these results as pharmacists continue to lead the 
way in delivering effective transitional care.
Inpatient medication review
Hospital admission appears to be an opportune time at which a 
pharmacist can comprehensively review a patient’s pharmaco-
therapy; this is especially of value where the hospitalization may 
have been drug-related or in patients with complex medication 
regimens, such as the multimorbid elderly receiving polyphar-
macy. Medication reviews allow hospital pharmacists to identify 
any MRPs and formulate their recommendations to resolve 
these issues with their fellow healthcare professionals. MRPs 
can be very costly to healthcare providers, as they can result 
in hospitalization, as well as increased LOS and cost of stay.84
In contrast to the primary care setting, a hospital phar-
macist can perform a more thorough medication review with 
access to all patient data and assess the pharmacotherapy in 
the context of the patient’s presenting conditions and symp-
toms. They are often carried out in conjunction with medi-
cines reconciliation on admission. Moreover, the pharmacist 
can interview the patient and have a face-to-face discussion 
with the prescriber regarding any unresolved MRPs. Although 
there are very few robust health economic analyses focusing 
on medication reviews by hospital pharmacists, a review of 
the literature found no studies where the intervention cost 
outweighed the benefit. Despite the shortage of definitive 
research regarding cost- and clinical effectiveness, the value 
of hospital pharmacist medication reviews is now commonly 
accepted in comparison to standard care. Nonetheless, addi-
tional research substantiating this belief would be beneficial.
Ward rounds
Traditionally, hospital pharmacists have provided their 
clinical services to wards by carrying out daily ward visits, 
where they address any MRPs identified with appropriate 
interventions. The pharmacist’s role in prescribing is usu-
ally retrospective, where there may be long delays between 
the time of prescription and the pharmacist’s intervention, 
increasing the risk for costly ADEs. Therefore, it may be more 
advantageous for a pharmacist to be present at the time of 
prescribing, providing their specialized knowledge when it 
may be needed most.85
It has been shown that pharmacist participation in consul-
tant-led ward rounds in addition to the ward-pharmacist visit 
allows for significantly more interventions to be achieved 
per patient in comparison to the ward-pharmacist visit 
alone.86 Although attending daily ward rounds may be time-
consuming for pharmacists, it is an excellent opportunity to 
prevent ADEs and significantly reduce healthcare costs.85–87 
Similarly, the presence of a pharmacist on a post-admission 
ward round allows for early amendment of discrepancies 
from the medication history and can result in reduced risk 
for patients and lower prescribing costs.88
Specialized roles
The literature is replete with publications that describe the 
pivotal role that pharmacist interventions can play in improv-
ing healthcare outcomes and decreasing costs in a variety 
of practice settings.9,74,89 In an ICU setting, pharmacists are 
valued practitioners, as they can provide advice to physicians 
regarding complex pharmaceutical regimens in critically ill 
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Pharmacist role in cost reduction
have a positive impact in this high-risk environment by pre-
venting ADEs, reducing morbidity and mortality, and limiting 
overall healthcare costs.70 A recent Dutch paper demonstrated 
that a pharmacist in an ICU setting can have a significant 
impact on reducing prescribing errors and preventable ADEs, 
bringing about cost savings even with limited time invest-
ment. The ICU physicians in this study were not accustomed 
to ward-based pharmacist recommendations, and yet the high 
acceptance rate of 74% emphasizes how clinically pertinent 
these interventions were.90
In the ED setting, pharmacists’ activities include the 
provision of medicines information, medication chart review, 
toxicology consultation, and eliminating medication errors at 
the earliest point of admission. A medication history ascer-
tained by an ED pharmacist with subsequent medicines rec-
onciliation increases the likelihood of obtaining an accurate 
medication chart for a patient early in their hospital stay.91 
Pharmacist interventions have been linked with significant 
cost-avoidance figures in this high-risk environment.69 One 
study from the US demonstrated that the implementation 
of a 24-hour ED pharmacy service allowed for pharmacist 
interventions to prevent serious patient harm and would 
extrapolate to an annual cost saving of $1,691,185.92
Against a backdrop of increasing antimicrobial resistance, 
pharmacists are major drivers in promoting antimicrobial 
stewardship worldwide.93 Many hospitals now have phar-
macists who specialize in this area of stewardship, ensuring 
the rational use of antimicrobials with improved patient 
outcomes, and are often involved in the development of the 
hospital’s antimicrobial guidelines. Streamlining antimicro-
bial therapy is a key responsibility of this specialized role, 
whereby cost savings are generated from discontinuing the 
inappropriate use of certain agents, and promoting the conver-
sion from parenteral to oral administration without negatively 
affecting patient care. These savings are primarily made 
through reduced antimicrobial costs and reduction in LOS.94 
One study showed that pharmacist involvement in surgical 
antibiotic prophylaxis contributed to a 52.1% lower mortality 
rate, a 10.2% reduction in LOS, and a 34.3% lower incidence 
of postoperative infections compared with hospitals without 
pharmacist involvement in surgical antibiotic prophylaxis.95
Chemotherapy services
The rise in cancer incidence worldwide has resulted in an 
increased number of prescriptions for antineoplastic agents. 
Chemotherapy regimens may be highly complex and are 
more susceptible to error, as they necessitate frequent dos-
age adjustments. Medication errors involving these regimens 
may be catastrophic due to the drugs’ narrow therapeutic 
index, and thus pharmacist involvement is crucial.96 One 
study showed that even though the overall  pharmacist 
intervention rate was low (1.59%), just over 50% of these 
interventions were considered to be higher than clinically 
“significant”, including 11% of cases being “very significant” 
or “extremely significant”, producing an annual net cost 
benefit of $116,493.97 This highlights that the presence of a 
pharmacist in a chemotherapy preparation unit can prevent 
ADEs in a high-risk environment and result in a noteworthy 
positive effect on hospital budgets.
Pharmacists in other clinical 
settings
Long-term care
Residents in long-term care are often elderly people with 
several comorbid conditions, who may be very susceptible 
to inappropriate prescribing. Although complex medication 
regimens are often required for these individuals, pharma-
cists can play a vital role in improving the overall quality of 
drug therapy.98 The pharmacist’s medication review saves 
doctors’ time; this is particularly the case for patients who 
are not reviewed opportunistically. Overall, the evidence for 
the benefit of pharmacists in long-term care settings is quite 
mixed. Pharmacists can improve clinical outcomes by reduc-
ing potentially inappropriate prescribing and MRPs; however, 
the majority of successful interventions in the literature were 
multidisciplinary in nature. One study involved pharmacists 
performing medication reviews, followed by discussion of 
MRPs with medical and nursing staff: 94% of the pharma-
cist’s recommendations were accepted, and the success was 
attributed to effective multidisciplinary communication.99 
Economic evaluations of pharmacist interventions in this 
setting are limited, but most studies have shown no significant 
difference in humanistic and economic outcomes.73
Ambulatory care clinics
Pharmacist-managed ambulatory care clinics are becoming 
increasingly more prevalent in North America. Most of these 
clinics are located in primary care medical centers, where phar-
macists perform patient assessments, provide collaborative 
drug therapy management, and can order medication therapy-
related tests. The delegation of some medication management 
responsibilities, such as prescribing, to an ambulatory care 
pharmacist frees up time for GPs and reduces patient waiting 
lists, resulting in increased patient satisfaction scores.100
However, the integration of these clinics into primary 
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 reimbursement for pharmacy services. A common imple-
mentation model for these services includes a disease-specific 
chronic care management model, whereby a pharmacist will 
focus on the management of one chronic disease in particular 
(eg, chronic obstructive pulmonary disease, type 2 diabetes). 
Studies from the US have demonstrated that pharmacists 
in this setting had a positive effect on both clinical and 
cost outcomes, whereby patients achieved their therapeutic 
goals, resulting in reduced hospital readmission rates.100,101 
Legislation changes may be required in some jurisdictions to 
allow for reimbursement of pharmacist services and further 
expansion of the pharmacist role in primary care, providing 
a valued service to underserved populations.
Conclusion
Studies have consistently demonstrated that pharmacists con-
tribute to reductions in costs in a wide variety of healthcare 
settings. However, several review articles have highlighted 
that some of the economic evaluations in the literature were 
of poor quality. Therefore, future studies with more robust 
study designs would be of great value to endorse the previ-
ous findings, and these should focus on identifying which 
pharmacist services and interventions are both effective 
and contribute to the greatest cost savings. High-quality 
studies of this nature would act as viable decision tools 
in choosing what clinical pharmacy services should be 
implemented. Lastly, while the economic effect of clinical 
pharmacy services is important, it is not the only aspect 
that must be taken into consideration. The impact that the 
service has on clinical and humanistic outcomes is also of 
great significance and must be considered when selecting 
what pharmacist-provided patient care services could be 
developed in the future.
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